[CAS NO. 113-24-6] Sodium 2-oxopropanoate
PRODUCTS SPECIFICATIONS [113-24-6]
DESCRIPTION [113-24-6]
Overview
| MDL | MFCD00002586 |
|---|---|
| Molecular Weight | 110.04 |
| Molecular Formula | C3H3NaO3 |
| SMILES | CC(C(O[Na])=O)=O |
Summary
IC50 & Target
|
Microbial Metabolite |
Human Endogenous Metabolite |
In Vitro
In the process of scavenging hydrogen peroxide, Sodium 2-oxopropanoate (Sodium pyruvate) is decarboxylated to lactate and hence diverted away from aerobic metabolism and further ROS generation. Under conditions in which pyruvate stimulated JNK1 activity, both mitochondrial and cytosolic ROS levels rose. An increase in JNK1 activity in a variety of different cell types over a range of pyruvate concentrations are observed
[1]
.
Sodium 2-oxopropanoate (Sodium pyruvate) is an effective scavenger of H
2
O
2
as well as of O
2
·-
, thereby protecting the lens against oxidative stress and consequent cataract formation, under in vitro as well as in vivo conditions, Sodium 2-oxopropanoate has also been shown to protect the lens proteins against glycation by competitively inhibiting the initial reaction between the sugar carbonyl and the protein -NH
2
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Neonatal rats are given a bolus of Sodium 2-oxopropanoate (Sodium pyruvate; 0.1-10 g/kg), and 1 h later, levels of JNK1 activity were determined in liver extracts. Sodium 2-oxopropanoate (Sodium pyruvate) addition resulted in a significant increase in JNK1 activity. Analysis of serum levels of Sodium 2-oxopropanoate in neonatal rats revealed that baseline levels of pyruvate are 0.30 mM. At the time of sacrifice, following the largest dose of Sodium 2-oxopropanoate, serum levels rose approximately sixfold to 1.84 mM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02151630 | Isfahan University of Medical Sciences |
Plantar Wart
|
May 2014 | Phase 2|Phase 3 |
| NCT00308243 | Emphycorp|Cellular Sciences, inc. |
Cystic Fibrosis
|
March 2006 | Phase 1 |
| NCT04824365 | Cellular Sciences, inc.|Missouri State University|Dynamic DNA Labs|Trinity Health Care|Family First Medical Research Center |
COVID-19
|
April 12, 2021 | Phase 2|Phase 3 |
| NCT00332215 | University of Minnesota|Cellular Sciences, inc. |
Cystic Fibrosis
|
February 2006 | Phase 1 |
| NCT00262613 | Emphycorp|Cellular Sciences, inc. |
Chronic Obstructive Pulmonary Disease (COPD)
|
September 2004 | Phase 2 |
| NCT00262652 | Emphycorp |
Moderate Asthma
|
January 2006 | Phase 1|Phase 2 |
| NCT04871815 | Cellular Sciences, inc.|Missouri State University|Dynamic DNA Labs|Trinity Health Care|Family First Medical Research Center |
Long COVID
|
April 27, 2021 | Phase 2|Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 908.76 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 9.0876 mL | 45.4380 mL | 90.8760 mL |
| 5 mM | 1.8175 mL | 9.0876 mL | 18.1752 mL |
| 10 mM | 0.9088 mL | 4.5438 mL | 9.0876 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (454.38 mM); Clear solution; Need ultrasonic
References
Synonyms